Clinical Trials Directory

Trials / Terminated

TerminatedNCT00782639

Renal Safety of Iopamidol Versus Iodixanol During Coronary Angiography in Diabetic Patients

RECARE (REnal Safety Following the Intra-Arterial Administration of Iopamidol vs. Iodixanol During Coronary AngiogRaphy in DiabEtic Patients)

Status
Terminated
Phase
Phase 4
Study type
Interventional
Enrollment
23 (actual)
Sponsor
Bracco Diagnostics, Inc · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to compare the incidence of contrast-induced nephropathy (CIN) following the administration of iopamidol-370 (Iopamiro-370) and iodixanol-320 (Visipaque 320) in patients with moderate-to-severe chronic kidney disease and diabetes mellitus undergoing cardiac angiography.

Detailed description

This was a Phase IV, multicenter, randomized, double-blind, parallel-group comparison of iopamidol-370 and iodixanol-320 in patients at high risk for CIN, i.e., patients with: * Stage 3 or 4 CKD (SCr level of ≥ 1.5 mg/dL for men and ≥1.3 mg/dL for women or eGFR between 15 and 50 mL/min, and * Diabetes mellitus who would undergo clinically indicated cardiac angiography procedures. Approximately 10 investigative centers were to participate in this study. This study was to enroll approximately 220 patients to ensure that 200 evaluable patients were able to complete the study according to this protocol. Patients were to be randomized to receive either iopamidol-370 or iodixanol-320. Each patient was to be evaluated for the occurrence of CIN within 48 to 72 hours postdose.

Conditions

Interventions

TypeNameDescription
DRUGIopamidol injection 76%Iopamiro-370 (Iopamidol injection 76%) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
DRUGiodixanolVisipaque 320 (iodixanol) injection is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution

Timeline

Start date
2009-03-01
Primary completion
2009-09-01
Completion
2009-09-01
First posted
2008-10-31
Last updated
2012-01-26
Results posted
2011-09-01

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00782639. Inclusion in this directory is not an endorsement.